Roche's Tecentriq turns I/O fight in lung cancer to a 3-way duel

Roche’s new immuno-oncology drug Tecentriq is ready for its close-up in lung cancer. The PD-L1 checkpoint inhibitor nabbed FDA approval for patients who’ve failed on a previous treatment, putting it in head-to-head competition with Merck & Co.’s Keytruda and Bristol-Myers Squibb’s Opdivo.

BMS to test Opdivo, Yervoy with AbbVie's $10B Rova-T

Bristol-Myers Squibb’s immunotherapy Opdivo has been powering ahead, racking up sales and new FDA approvals one after another. And with cancer-fighting immunotherapy cocktails seen as the next wave in oncology, the Big Pharma has teamed up with a range of companies to test Opdivo in combination with its partners’ meds.